More articles from Current Drug Therapy
Recombinant human PTH 1-34 (Forteo): An anabolic drug for osteoporosisWe have an important new drug for osteoporosis. Now who should get it? And who will pay for it?
- The newer antimuscarinic drugs: Bladder control with less dry mouth
Tolterodine (Detrol) and extended-release oxybutynin (Ditropan XL) are replacing immediate-release oxybutynin, being better tolerated.
- Inflammatory bowel disease: Sorting out the treatment options
Options now include aminosalicylates, steroids, azathioprine, 6-mercaptopurine, cyclosporine, methotrexate, infliximab, heparin, and perhaps even antimicrobials and nicotine. How to choose?
- Aromatase inhibitors in breast cancer: Current and evolving roles
Aromatase inhibitors are finding new uses. Already established for treating metastatic breast cancer in postmenopausal women, they are gaining acceptance as adjuvant treatment as well.
- Statins and osteoporosis: Can these lipid-lowering drugs also bolster bones?
Statin drugs may promote bone formation. Although the clinical data are limited and mixed, they may point the way to better drugs for osteoporosis.
- How to prevent, recognize, and treat drug-induced nephrotoxicity
How drugs injure the kidney, who is at risk, and how to prevent renal injury.
- Dofetilide (Tikosyn): A new drug to control atrial fibrillation
The pharmacology of dofetilide, the evidence of its effectiveness, and the appropriate precautions in using it.
- Phenylpropanolamine and stroke: The study, the FDA ruling, the implications
The FDA, after a recent study, asked manufacturers to pull dozens of products from the shelves.
- Cisapride: Limited access and alternatives
Linked to cases of fatal arrhythmias, cisapride can still be prescribed, but only under a strict limited-access program.
- Using viral load, CD4+ levels, and clinical response to guide antiviral therapy for HIV
A summary of the most recent guidelines from the International AIDS Society.